Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1537

Related Citations for PubMed (Select 15802970)

1.
2.
3.
4.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

5.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
6.

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.

Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S.

Vaccine. 1999 Feb 26;17(7-8):653-9.

PMID:
10067670
7.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

8.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.

Vaccine. 2008 Oct 3;26(42):5393-9. doi: 10.1016/j.vaccine.2008.07.084. Epub 2008 Aug 14.

PMID:
18706956
9.

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs.

Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang SM.

Vaccine. 2008 Jun 19;26(26):3352-61. doi: 10.1016/j.vaccine.2008.03.055. Epub 2008 Apr 11.

PMID:
18468740
11.
12.

Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine.

Tamura SI, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A.

Eur J Immunol. 1992 Feb;22(2):477-81.

PMID:
1537382
15.

Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice.

Olsen CW, McGregor MW, Dybdahl-Sissoko N, Schram BR, Nelson KM, Lunn DP, Macklin MD, Swain WF, Hinshaw VS.

Vaccine. 1997 Jul;15(10):1149-56.

PMID:
9269061
17.

Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.

de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA.

J Virol. 2005 Oct;79(19):12401-7.

18.

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G.

Vaccine. 2005 Dec 30;23(50):5751-9. Epub 2005 Aug 15.

PMID:
16143432
19.

Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO.

Clin Vaccine Immunol. 2011 Dec;18(12):2010-7. doi: 10.1128/CVI.05206-11. Epub 2011 Oct 26.

20.

Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.

Crevar CJ, Ross TM.

Virol J. 2008 Oct 28;5:131. doi: 10.1186/1743-422X-5-131.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk